Sam Wadsworth
As Chief Scientific Officer at Aspect Biosystems, Sam is responsible for the biological scientific innovation and development. He co-founded the company in 2013 and currently leads our technical efforts in developing cell-containing bioprinted tissues to treat currently incurable diseases. In 2023, based on highly promising pre-clinical data, Aspect partnered with Novo Nordisk to co-develop bioprinted tissue therapeutics for diabetes and obesity. This deal worth up to $2.6Bn + royalties, is the largest bioprinting deal ever, and one of the largest pre-clinical deals in Canadian history. Sam holds a PhD in respiratory cell biology from the University of Nottingham."
Aspect Biosystems
Synthetic Biology Frontiers in Transplantation: Engineering Durable Therapeutic Solutions
-
This cutting-edge session explores the intersection of synthetic biology, materials science, and transplantation medicine to address key challenges in cell, tissue, and organ transplantation. We'll examine innovative approaches to enhance transplant durability, improve integration with host systems, and advance the field of regenerative medicine. Examples include: genetically engineered cells for enhanced survival, 3d-printed scaffolds and organoids, advances in xenotransplantation, and others.
Conference Pass
2,495
USD
Keynotes & Firesides
Workshops & Breakouts
1:1 Partnering App
Meals & Receptions
Session Recordings
Until Friday April 18th
Full Rate:
$3,495
